Microbial Contract Biomanufacturing Market, 2020-2030

The growing pipeline of biologics that can be produced in microbial systems, such as antibody fragments and plasmid-based therapies, is anticipated to offer lucrative opportunities to service providers serving this niche, but growing market segment

Roots Analysis has announced the addition of the “Microbial Contract Biomanufacturing Market, 2020-2030” report to its list of offerings.

Despite mammalian cell cultures being the preferred manufacturing approach for biologics, recent advances in microbial fermentation have enabled the development of versatile biomanufacturing systems, which are both robust and cost friendly. Presently, a number of service provider companies claim to offer end-to-end solutions, ranging from product development to commercial production, for microbial biologics. Given the obvious advantages of outsourcing, drug developers are likely to continue relying on contract service providers for various aspects of their respective microbial biologic development programs.

Key Market Insights
Over 115 CMOs claim to offer manufacturing services for microbial biologics
The microbial contract biomanufacturing market is highly fragmented, featuring a mix of small, mid-sized, large and very large players. It is worth mentioning that more than 50% of CMOs mentioned in the report, have the necessary capabilities to manufacture biologics across all scales of operation (preclinical, clinical and commercial).

Presently, more than 70% of service providers use bacterial expression systems
Recently, a number of microbial biologics manufacturers are shifting to yeast-based production systems. It is also worth highlighting that close to 30% of CMOs, identified in this research, claim to have the required capabilities to manufacture biologics using both bacterial and yeast-based systems.

Europe is currently regarded as a key manufacturing hub for microbial biologics
There are more than 150 manufacturing facilities, with microbial fermentation capabilities, worldwide; of these, 43% are in Europe, followed by North America (31%). On the other hand, prominent regions in the Asia Pacific and Middle East, where microbial biologics are manufactured, include (in decreasing order of number of resident manufacturing facilities) China, India, Japan, Australia and Israel.
Several partnerships were established in this domain, during the period 2016-2020
Majority of the deals recorded in the report, were established in 2019. Further, a large number (~25%) of the partnerships were observed to be focused on the production of microbial biologics; this is followed by process development and manufacturing agreements (20%).

Further, multiple expansion initiatives were undertaken by CMOs, since 2016
More than 30% of expansion projects over the last few years were focused on the establishment of new facilities, followed by those involving the expansion of existing manufacturing facilities (28%). Further, 50% of the expansion initiatives mentioned in the report, were in undertaken by stakeholder companies in Europe, followed North America (39%).

Big pharma players have also been active in this upcoming field
Around 60% of the initiatives undertaken by big pharma were reported in the period 2016-2020. Of these, 57% involved the establishment of strategic partnerships with other industry stakeholders. It is worth highlighting that, in terms of type of biologic, close to 49% of these initiatives were focused on recombinant proteins.

North America and Europe are anticipated to capture over 80% share (in terms of service revenues) of the market, by 2030
At present, more than 60% of the total revenues are generated from commercialized microbial biologics, and this trend is unlikely to change significantly in short to mid-term. Further, it is worth mentioning that the contract biomanufacturing market for microbial biologics in the Middle East and North Africa is anticipated to grow at a relatively faster rate (10.3%), followed by Asia Pacific (9%).
The USD 9.3 billion (by 2030) financial opportunity within the microbial contract biomanufacturing market has been analyzed across the following segments:

Type of Product
• API
• FDF

Type of Biologic
• Proteins
• Enzymes
• Growth Hormones
• Antibody based Drugs
• Others (plasmid DNA, probiotics, microbiome-based biologics)

Type of Microbial Expression System
• Bacteria
• Yeast
• Others (Algae and fungi)

Scale of Operation
• Commercial
• Preclinical / Clinical

Type of End User
• Small Companies
• Mid-sized Companies
• Large / Very Large Companies

Key Geographical Regions
• North America
• Europe
• Asia Pacific
• Middle East and North Africa
• Latin America

The report features inputs from eminent industry stakeholders, according to whom, currently, over 50% operations related to both API and FDF manufacturing of microbial biologics are outsourced to third party service providers. The report includes detailed transcripts of discussions held with the following experts:
• Gaurav Kaushik (Chief Executive Officer and Managing Director, Meteoric Biopharmaceuticals)
• Debbie Pinkston (Vice President, Sales and Business Development, List Biological Laboratories)
• Andrea Conforto (Sales and Marketing, Bioservices Director, Olon)
• Max Rossetto (General Manager, Business Development, Luina Bio)
• Rob van Dijk (Business Development Manager, WACKER Biotech)

The research covers profiles of key players (listed below); each profile features an overview of the company, information related to its microbial manufacturing focused service portfolio, production facilities and capabilities, and an informed future outlook.
• AGC Biologics
• Aldevron
• BioVectra
• EirGenix
• Etinpro
• Eurogentec
• Northway Biotechpharma
• Ology Bioservices
• Porton Biopharma
• Stelis Biopharma

For more information, please click on the following link:
https://www.rootsanalysis.com/reports/microbial-contract-biomanufacturing-market/request-sample.html
About Roots Analysis
Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com
Contact Information
Roots Analysis Private Limited
Gaurav Chaudhary
+1 (415) 800 3415
Gaurav.Chaudhary@rootsanalysis.com

#microbial contract biomanufacturing market

What is GEEK

Buddha Community

Brain Crist

1594753020

Citrix Bugs Allow Unauthenticated Code Injection, Data Theft

Multiple vulnerabilities in the Citrix Application Delivery Controller (ADC) and Gateway would allow code injection, information disclosure and denial of service, the networking vendor announced Tuesday. Four of the bugs are exploitable by an unauthenticated, remote attacker.

The Citrix products (formerly known as NetScaler ADC and Gateway) are used for application-aware traffic management and secure remote access, respectively, and are installed in at least 80,000 companies in 158 countries, according to a December assessment from Positive Technologies.

Other flaws announced Tuesday also affect Citrix SD-WAN WANOP appliances, models 4000-WO, 4100-WO, 5000-WO and 5100-WO.

Attacks on the management interface of the products could result in system compromise by an unauthenticated user on the management network; or system compromise through cross-site scripting (XSS). Attackers could also create a download link for the device which, if downloaded and then executed by an unauthenticated user on the management network, could result in the compromise of a local computer.

“Customers who have configured their systems in accordance with Citrix recommendations [i.e., to have this interface separated from the network and protected by a firewall] have significantly reduced their risk from attacks to the management interface,” according to the vendor.

Threat actors could also mount attacks on Virtual IPs (VIPs). VIPs, among other things, are used to provide users with a unique IP address for communicating with network resources for applications that do not allow multiple connections or users from the same IP address.

The VIP attacks include denial of service against either the Gateway or Authentication virtual servers by an unauthenticated user; or remote port scanning of the internal network by an authenticated Citrix Gateway user.

“Attackers can only discern whether a TLS connection is possible with the port and cannot communicate further with the end devices,” according to the critical Citrix advisory. “Customers who have not enabled either the Gateway or Authentication virtual servers are not at risk from attacks that are applicable to those servers. Other virtual servers e.g. load balancing and content switching virtual servers are not affected by these issues.”

A final vulnerability has been found in Citrix Gateway Plug-in for Linux that would allow a local logged-on user of a Linux system with that plug-in installed to elevate their privileges to an administrator account on that computer, the company said.

#vulnerabilities #adc #citrix #code injection #critical advisory #cve-2020-8187 #cve-2020-8190 #cve-2020-8191 #cve-2020-8193 #cve-2020-8194 #cve-2020-8195 #cve-2020-8196 #cve-2020-8197 #cve-2020-8198 #cve-2020-8199 #denial of service #gateway #information disclosure #patches #security advisory #security bugs

Stella Wilson

1612876798